Symbols / RAPT
RAPT Chart
About
RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. RAPT Therapeutics, Inc. is a subsidiary of Bristol-Myers Squibb Company.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.68B |
| Enterprise Value | 1.45B | Income | -105.64M | Sales | — |
| Book/sh | 9.02 | Cash/sh | 5.68 | Dividend Yield | — |
| Payout | 0.00% | Employees | 60 | IPO | — |
| P/E | — | Forward P/E | -18.66 | PEG | — |
| P/S | — | P/B | 6.42 | P/C | — |
| EV/EBITDA | -12.99 | EV/Sales | — | Quick Ratio | 11.76 |
| Current Ratio | 12.04 | Debt/Eq | 1.71 | LT Debt/Eq | — |
| EPS (ttm) | -11.66 | EPS next Y | -3.10 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-05 | ROA | -51.35% |
| ROE | -85.37% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 28.96M |
| Shs Float | 16.85M | Short Float | 12.36% | Short Ratio | 1.26 |
| Short Interest | — | 52W High | 57.98 | 52W Low | 5.66 |
| Beta | 0.49 | Avg Volume | 2.37M | Volume | 1.00M |
| Target Price | $58.00 | Recom | Hold | Prev Close | $57.93 |
| Price | $57.93 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$58.00
Mean price target
2. Current target
$57.93
Latest analyst target
3. DCF / Fair value
$-28.83
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$57.93
Low
$58.00
High
$58.00
Mean
$58.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-21 | down | Barclays | Overweight → Equal-Weight | $58 |
| 2026-01-21 | down | Leerink Partners | Outperform → Market Perform | $58 |
| 2026-01-20 | down | Wells Fargo | Overweight → Equal-Weight | $58 |
| 2026-01-20 | down | LifeSci Capital | Outperform → Market Perform | — |
| 2026-01-20 | down | TD Cowen | Buy → Hold | — |
| 2026-01-20 | down | HC Wainwright & Co. | Buy → Neutral | $58 |
| 2026-01-20 | down | Clear Street | Buy → Hold | $58 |
| 2025-12-18 | init | TD Cowen | — → Buy | — |
| 2025-11-12 | main | JP Morgan | Overweight → Overweight | $57 |
| 2025-11-07 | main | Barclays | Overweight → Overweight | $56 |
| 2025-11-03 | main | Wells Fargo | Overweight → Overweight | $72 |
| 2025-10-27 | main | HC Wainwright & Co. | Buy → Buy | $72 |
| 2025-10-27 | init | Guggenheim | — → Buy | $70 |
| 2025-10-21 | main | Wells Fargo | Overweight → Overweight | $48 |
| 2025-10-21 | main | Barclays | Overweight → Overweight | $58 |
| 2025-10-21 | main | Clear Street | Buy → Buy | $60 |
| 2025-10-20 | up | JP Morgan | Neutral → Overweight | $55 |
| 2025-10-13 | init | Barclays | — → Overweight | $35 |
| 2025-09-30 | main | Clear Street | Buy → Buy | $41 |
| 2025-09-26 | up | Leerink Partners | Market Perform → Outperform | $37 |
- Rapt Therapeutics stock hits 52-week high at 57.87 USD - Investing.com hu, 19 Feb 2026 19
- Avoiding Lag: Real-Time Signals in (RAPT) Movement - Stock Traders Daily Sat, 21 Feb 2026 14
- Why Rapt Therapeutics Stock Soared Today - The Motley Fool ue, 20 Jan 2026 08
- Assessing RAPT Therapeutics (RAPT) Valuation After A Sharp Share Price Surge - Yahoo Finance Fri, 23 Jan 2026 08
- RTW INVESTMENTS, LP Acquires Additional Shares in RAPT Therapeutics Inc - GuruFocus Sat, 21 Feb 2026 05
- GSK Digs In On Allergies With $2.2 Billion Rapt Therapeutics Buyout - Investor's Business Daily ue, 20 Jan 2026 08
- Why Rapt Therapeutics Stock Soared Today - Nasdaq ue, 20 Jan 2026 08
- RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT - Business Wire hu, 05 Feb 2026 08
- RAPT THERAPEUTICS INC (NASDAQ:RAPT) Shows High Technical and Pattern Scores Ahead of Potential Breakout - ChartMill Wed, 18 Feb 2026 13
- Big Picture: Is RAPT stock a smart retirement pick - Earnings Beat & Community Shared Stock Ideas - baoquankhu1.vn ue, 24 Feb 2026 17
- GSK acquires RAPT Therapeutics for $2.2bn - Pharmaceutical Technology ue, 20 Jan 2026 08
- RAPT Therapeutics, Inc. (NASDAQ:RAPT) surges 5.3%; individual investors who own 34% shares profited along with institutions - Yahoo Finance Mon, 15 Dec 2025 08
- Top 2% Biotech Rockets After Topping Roche In A Key Test - Investor's Business Daily Mon, 20 Oct 2025 07
- RAPT Therapeutics Announces Pricing of Public Offering of Common Stock - Yahoo Finance ue, 21 Oct 2025 07
- Biggest Market Mover: RAPT Therapeutics Stock Soars After GSK $2.2B Acquisition Deal - Yahoo Finance ue, 20 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 4956 | — | — | Stock Award(Grant) at price 0.00 per share. | GRAY MARY ANN | Director | — | 2026-01-30 00:00:00 | D |
| 1 | 4956 | — | — | Stock Award(Grant) at price 0.00 per share. | DOMBKOWSKI ASHLEY L | Director | — | 2026-01-30 00:00:00 | D |
| 2 | 4956 | — | — | Stock Award(Grant) at price 0.00 per share. | BRAUNSTEIN SCOTT N. | Director | — | 2026-01-30 00:00:00 | D |
| 3 | 4956 | — | — | Stock Award(Grant) at price 0.00 per share. | LYONS-WILLIAMS LORI | Director | — | 2026-01-30 00:00:00 | D |
| 4 | 4956 | — | — | Stock Award(Grant) at price 0.00 per share. | GIORDANO MICHAEL F | Director | — | 2026-01-30 00:00:00 | D |
| 5 | 4956 | — | — | Stock Award(Grant) at price 0.00 per share. | KOZICK LINDA | Director | — | 2026-01-30 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -134.90M | -125.85M | -84.75M | -68.21M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -129.87M | -116.80M | -83.84M | -69.20M |
| ReconciledDepreciation | 1.20M | 1.22M | 1.05M | 996.00K |
| EBITDA | -134.90M | -125.85M | -84.75M | -68.21M |
| EBIT | -136.10M | -127.06M | -85.80M | -69.21M |
| NormalizedIncome | -129.87M | -116.80M | -83.84M | -69.20M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -129.87M | -116.80M | -83.84M | -69.20M |
| TotalExpenses | 136.10M | 127.06M | 87.32M | 73.02M |
| TotalOperatingIncomeAsReported | -136.10M | -127.06M | -85.80M | -69.21M |
| DilutedAverageShares | 5.10M | 4.79M | 4.07M | 3.42M |
| BasicAverageShares | 5.10M | 4.79M | 4.07M | 3.42M |
| DilutedEPS | -25.52 | -24.40 | -20.64 | -20.24 |
| BasicEPS | -25.52 | -24.40 | -20.64 | -20.24 |
| DilutedNIAvailtoComStockholders | -129.87M | -116.80M | -83.84M | -69.20M |
| NetIncomeCommonStockholders | -129.87M | -116.80M | -83.84M | -69.20M |
| NetIncome | -129.87M | -116.80M | -83.84M | -69.20M |
| NetIncomeIncludingNoncontrollingInterests | -129.87M | -116.80M | -83.84M | -69.20M |
| NetIncomeContinuousOperations | -129.87M | -116.80M | -83.84M | -69.20M |
| TaxProvision | 0.00 | |||
| PretaxIncome | -129.87M | -116.80M | -83.84M | -69.20M |
| OtherIncomeExpense | 6.24M | 10.26M | 1.96M | 5.00K |
| OtherNonOperatingIncomeExpenses | 6.24M | 10.26M | 1.96M | 5.00K |
| OperatingIncome | -136.10M | -127.06M | -85.80M | -69.21M |
| OperatingExpense | 136.10M | 127.06M | 87.32M | 73.02M |
| ResearchAndDevelopment | 107.22M | 101.00M | 67.08M | 56.98M |
| SellingGeneralAndAdministration | 28.88M | 26.06M | 20.24M | 16.04M |
| GeneralAndAdministrativeExpense | 28.88M | 26.06M | 20.24M | 16.04M |
| OtherGandA | 28.88M | 26.06M | 20.24M | 16.04M |
| TotalRevenue | 0.00 | 0.00 | 1.53M | 3.81M |
| OperatingRevenue | 0.00 | 0.00 | 1.53M | 3.81M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 16.50M | 4.30M | 4.28M | 3.69M |
| ShareIssued | 16.50M | 4.30M | 4.28M | 3.69M |
| TotalDebt | 4.49M | 6.91M | 8.99M | 0.00 |
| TangibleBookValue | 189.90M | 147.03M | 245.17M | 186.38M |
| InvestedCapital | 189.90M | 147.03M | 245.17M | 186.38M |
| WorkingCapital | 186.88M | 139.95M | 238.47M | 183.38M |
| NetTangibleAssets | 189.90M | 147.03M | 245.17M | 186.38M |
| CapitalLeaseObligations | 4.49M | 6.91M | 8.99M | 0.00 |
| CommonStockEquity | 189.90M | 147.03M | 245.17M | 186.38M |
| TotalCapitalization | 189.90M | 147.03M | 245.17M | 186.38M |
| TotalEquityGrossMinorityInterest | 189.90M | 147.03M | 245.17M | 186.38M |
| StockholdersEquity | 189.90M | 147.03M | 245.17M | 186.38M |
| GainsLossesNotAffectingRetainedEarnings | 50.00K | 103.00K | -26.00K | -206.00K |
| OtherEquityAdjustments | 50.00K | 103.00K | -26.00K | -206.00K |
| RetainedEarnings | -614.55M | -484.68M | -367.88M | -284.05M |
| AdditionalPaidInCapital | 804.39M | 631.61M | 613.07M | 470.63M |
| CapitalStock | 13.00K | 3.00K | 3.00K | 3.00K |
| CommonStock | 13.00K | 3.00K | 3.00K | 3.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 50.42M | 26.29M | 21.04M | 12.26M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 2.07M | 4.46M | 6.82M | 2.66M |
| NonCurrentDeferredLiabilities | 0.00 | 2.66M | ||
| NonCurrentDeferredRevenue | 0.00 | 511.00K | ||
| LongTermDebtAndCapitalLeaseObligation | 2.07M | 4.46M | 6.82M | 0.00 |
| LongTermCapitalLeaseObligation | 2.07M | 4.46M | 6.82M | 0.00 |
| CurrentLiabilities | 48.35M | 21.84M | 14.22M | 9.60M |
| OtherCurrentLiabilities | 57.00K | 109.00K | 32.00K | 254.00K |
| CurrentDeferredLiabilities | 0.00 | 1.02M | ||
| CurrentDeferredRevenue | 0.00 | 1.02M | ||
| CurrentDebtAndCapitalLeaseObligation | 2.42M | 2.45M | 2.17M | |
| CurrentCapitalLeaseObligation | 2.42M | 2.45M | 2.17M | 0.00 |
| PensionandOtherPostRetirementBenefitPlansCurrent | 6.72M | 6.30M | 4.62M | 3.65M |
| PayablesAndAccruedExpenses | 39.15M | 12.98M | 7.40M | 4.67M |
| CurrentAccruedExpenses | 2.87M | 7.80M | 4.04M | 2.67M |
| Payables | 36.27M | 5.18M | 3.37M | 2.00M |
| OtherPayable | 35.00M | |||
| AccountsPayable | 1.27M | 5.18M | 3.37M | 2.00M |
| TotalAssets | 240.32M | 173.33M | 266.21M | 198.64M |
| TotalNonCurrentAssets | 5.09M | 11.55M | 13.52M | 5.66M |
| OtherNonCurrentAssets | 389.00K | 3.87M | 4.04M | 2.92M |
| NetPPE | 4.70M | 7.68M | 9.48M | 2.74M |
| AccumulatedDepreciation | -10.08M | -9.37M | -8.25M | -7.68M |
| GrossPPE | 14.78M | 17.04M | 17.73M | 10.43M |
| Leases | 3.29M | 3.29M | 3.29M | 3.29M |
| OtherProperties | 10.37M | 12.63M | 13.50M | 6.29M |
| MachineryFurnitureEquipment | 1.12M | 1.12M | 935.00K | 839.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 235.24M | 161.78M | 252.69M | 192.97M |
| OtherCurrentAssets | 4.18M | 2.92M | 3.63M | 3.32M |
| PrepaidAssets | 3.32M | |||
| CashCashEquivalentsAndShortTermInvestments | 231.06M | 158.86M | 249.07M | 189.65M |
| OtherShortTermInvestments | 61.32M | 111.38M | 210.12M | 165.63M |
| CashAndCashEquivalents | 169.74M | 47.48M | 38.95M | 24.03M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -83.42M | -98.17M | -71.62M | -61.78M |
| IssuanceOfCapitalStock | 152.01M | 0.00 | 129.79M | 139.46M |
| CapitalExpenditure | -122.00K | -1.12M | -845.00K | -755.00K |
| IncomeTaxPaidSupplementalData | 0.00 | |||
| EndCashPosition | 169.74M | 47.48M | 38.95M | 24.03M |
| BeginningCashPosition | 47.48M | 38.95M | 24.03M | 24.92M |
| ChangesInCash | 122.26M | 8.53M | 14.92M | -891.00K |
| FinancingCashFlow | 152.85M | 1.45M | 131.18M | 141.48M |
| CashFlowFromContinuingFinancingActivities | 152.85M | 1.45M | 131.18M | 141.48M |
| ProceedsFromStockOptionExercised | 845.00K | 1.45M | 1.39M | 2.02M |
| NetCommonStockIssuance | 152.01M | 0.00 | 129.79M | 139.46M |
| CommonStockIssuance | 152.01M | 0.00 | 129.79M | 139.46M |
| InvestingCashFlow | 52.70M | 104.13M | -45.49M | -81.35M |
| CashFlowFromContinuingInvestingActivities | 52.70M | 104.13M | -45.49M | -81.35M |
| NetInvestmentPurchaseAndSale | 52.82M | 105.26M | -44.65M | -80.59M |
| SaleOfInvestment | 135.04M | 266.75M | 146.21M | 84.39M |
| PurchaseOfInvestment | -82.22M | -161.50M | -190.86M | -164.98M |
| NetPPEPurchaseAndSale | -122.00K | -1.12M | -845.00K | -755.00K |
| SaleOfPPE | 0.00 | 0.00 | ||
| PurchaseOfPPE | -122.00K | -1.12M | -845.00K | -755.00K |
| OperatingCashFlow | -83.30M | -97.05M | -70.77M | -61.03M |
| CashFlowFromContinuingOperatingActivities | -83.30M | -97.05M | -70.77M | -61.03M |
| ChangeInWorkingCapital | 25.91M | 5.50M | -1.33M | -4.30M |
| ChangeInOtherWorkingCapital | -1.53M | -3.47M | ||
| ChangeInOtherCurrentLiabilities | -2.85M | -2.71M | -2.10M | 0.00 |
| ChangeInPayablesAndAccruedExpense | 26.54M | 7.33M | 3.71M | 933.00K |
| ChangeInPayable | 26.54M | 7.33M | 3.71M | 933.00K |
| ChangeInAccountPayable | -8.46M | 7.33M | 3.71M | 933.00K |
| ChangeInPrepaidAssets | 2.22M | 871.00K | -1.42M | -1.76M |
| OtherNonCashItems | 2.34M | 2.33M | 1.76M | |
| StockBasedCompensation | 19.93M | 17.09M | 11.26M | 9.95M |
| AmortizationOfSecurities | -2.81M | -5.74M | -296.00K | 1.27M |
| DepreciationAmortizationDepletion | 1.20M | 1.22M | 1.05M | 996.00K |
| DepreciationAndAmortization | 1.20M | 1.22M | 1.05M | 996.00K |
| OperatingGainsLosses | -655.00K | 627.00K | 258.00K | |
| NetForeignCurrencyExchangeGainLoss | 0.00 | -655.00K | 627.00K | 258.00K |
| GainLossOnSaleOfPPE | 0.00 | |||
| NetIncomeFromContinuingOperations | -129.87M | -116.80M | -83.84M | -69.20M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for RAPT
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|